| abstract |
FIELD: medicine, pharmaceutics. n SUBSTANCE: there are described new compounds of formula I or their pharmaceutically acceptable salts, wherein R 1 means phenyl once or twice substituted by C 1-6 alkyl, C 1-6 alkoxy, halogen or 5-6-merous heteroaryl; R 2 is phenyl once or twice substituted by C 1-6 alkyl, C 1-6 alkoxy, halogen, halogen-C 1-6 alkyl, halogen-C 1-6 alkoxy, C 1-6 alkylsulphonyl, nitrile, etc. R 3 means H or C 1-6 alkyl; X - -O-, -NR a -,-S(O) m - or CR b R c , wherein R a - H, C 1-6 alkyl or C 1-6 alkylcarbonyl; R b and R c mean H or together with the atom to which they are attached, form 5-merous cycle additionally containing 2 oxygen atoms; m is equal to 0-2; Y means -NR c -, wherein R c - H or C 1-6 alkyl. n EFFECT: compounds can find application in medicine for treating autoimmune and inflammatory diseases related to P2X7 purinoceptor. n 15 cl, 1 tbl, 10 ex |